Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis.
Karpouzas GA, Ormseth SR, van Riel PLCM, Gonzalez-Gay MA, Corrales A, Rantapää-Dahlqvist S, Sfikakis PP, Dessein P, Tsang L, Hitchon C, El-Gabalawy H, Pascual-Ramos V, Contreras-Yáñez I, Colunga-Pedraza IJ, Galarza-Delgado DA, Azpiri-Lopez JR, Semb AG, Misra DP, Hauge EM, Kitas G. Karpouzas GA, et al. Among authors: el gabalawy h. RMD Open. 2024 Jul 23;10(3):e004546. doi: 10.1136/rmdopen-2024-004546. RMD Open. 2024. PMID: 39043615 Free PMC article.
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.
Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Keeling SO, et al. J Rheumatol. 2007 Mar;34(3):623-33. J Rheumatol. 2007. PMID: 17343310 Review.
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers.
Syversen SW, Landewe R, van der Heijde D, Bathon JM, Boers M, Bykerk VP, Fitzgerald O, Gladman DD, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus V, Kvien TK, Mease PJ, Ostergaard M, Ritchlin CJ, Tak PP, Taylor WJ, Maksymowych WP. Syversen SW, et al. J Rheumatol. 2009 Aug;36(8):1769-84. doi: 10.3899/jrheum.090262. J Rheumatol. 2009. PMID: 19671812 Review.
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria.
Maksymowych WP, Landewé R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA, van der Heijde D. Maksymowych WP, et al. J Rheumatol. 2009 Aug;36(8):1785-91. doi: 10.3899/jrheum.090346. J Rheumatol. 2009. PMID: 19671813
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.
Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewé R, Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy H, Aletaha D, Inman RD, Kraus VB, Kvien TK, van der Heijde D. Maksymowych WP, et al. J Rheumatol. 2009 Aug;36(8):1792-9. doi: 10.3899/jrheum090347. J Rheumatol. 2009. PMID: 19671814
170 results